Comparative Efficacy and Safety of Biosimilar Bevacizumab (Stivant®) versus Reference Product (Avastin®) in Prethreshold Type I Retinopathy of Prematurity
Stivant<sup>®</sup> exhibited noninferiority to Avastin<sup>®</sup> in efficacy and demonstrated a comparable safety profile in treating prethreshold type I ROP. A definite conclusion requires more extended studies with a larger sample size.
Authors
- Mehrdad Motamed Shariati (ORCID: https://orcid.org/0000-0001-8680-5560)
- Majid Abrishami (ORCID: https://orcid.org/0000-0003-2288-2780)
- Elham Bakhtiari (ORCID: https://orcid.org/0000-0002-1582-3961)
- Mojtaba Abrishami (ORCID: https://orcid.org/0000-0003-2001-7929)
- Nasser Shoeibi (ORCID: https://orcid.org/0000-0003-3544-0105)
- Seyedeh Maryam Hosseini (ORCID: https://orcid.org/0000-0002-4233-9243)
- Mohammad-Reza Ansari-Astaneh
- Zohreh Golmohammadi
- Mehdi Sakhayi
Institutions
- Mashhad University of Medical Sciences (IR)
- University of Toronto (CA)
Publication Details
- Journal
- Journal of Current Ophthalmology
- Published
- 2024-10-01
- DOI
- https://doi.org/10.4103/joco.joco_178_24
- Primary Topic
- Retinopathy of Prematurity Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00